PT828724E - Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2 - Google Patents
Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2Info
- Publication number
- PT828724E PT828724E PT96913412T PT96913412T PT828724E PT 828724 E PT828724 E PT 828724E PT 96913412 T PT96913412 T PT 96913412T PT 96913412 T PT96913412 T PT 96913412T PT 828724 E PT828724 E PT 828724E
- Authority
- PT
- Portugal
- Prior art keywords
- diaril
- oxygenates
- cox
- formula
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Polyesters Or Polycarbonates (AREA)
- Furan Compounds (AREA)
- Handcart (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/443,620 US5691374A (en) | 1995-05-18 | 1995-05-18 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PT828724E true PT828724E (pt) | 2002-05-31 |
Family
ID=23761534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT96913412T PT828724E (pt) | 1995-05-18 | 1996-05-15 | Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5691374A (pt) |
EP (1) | EP0828724B1 (pt) |
JP (1) | JPH11505534A (pt) |
AT (1) | ATE210124T1 (pt) |
AU (1) | AU707773B2 (pt) |
CA (1) | CA2219129A1 (pt) |
DE (1) | DE69617676T2 (pt) |
DK (1) | DK0828724T3 (pt) |
ES (1) | ES2168471T3 (pt) |
PT (1) | PT828724E (pt) |
WO (1) | WO1996036623A1 (pt) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9602877D0 (en) * | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
US5807873A (en) * | 1996-04-04 | 1998-09-15 | Laboratories Upsa | Diarylmethylidenefuran derivatives and their uses in therapeutics |
US6180651B1 (en) | 1996-04-04 | 2001-01-30 | Bristol-Myers Squibb | Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics |
RO118566B1 (ro) * | 1996-11-19 | 2003-07-30 | Searle & Co | Metoda pentru prevenirea si tratamentul unei boli asociata cu angiogeneza |
US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
FR2770131A1 (fr) * | 1997-10-27 | 1999-04-30 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
FR2771005B1 (fr) * | 1997-11-18 | 2002-06-07 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
CA2320290A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of cyclooxygenase-2 |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
CO5261541A1 (es) * | 1999-05-14 | 2003-03-31 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de la migrana |
CO5190664A1 (es) | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
ATE291019T1 (de) | 1999-12-03 | 2005-04-15 | Pfizer Prod Inc | Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen |
DE60004001T2 (de) | 1999-12-03 | 2004-04-15 | Pfizer Products Inc., Groton | Acetylenderivate zur Verwendung als schmerzstillendes oder entzündungshemmendes Mittel |
TR200302047T4 (tr) | 1999-12-03 | 2004-01-21 | Pfizer Products Inc. | Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri. |
ES2193921T3 (es) | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
US6465509B2 (en) * | 2000-06-30 | 2002-10-15 | Merck Frosst Canada & Co. | Pyrones as inhibitors of cyclooxygenase-2 |
US7695736B2 (en) | 2001-04-03 | 2010-04-13 | Pfizer Inc. | Reconstitutable parenteral composition |
EP1273582B1 (en) | 2001-07-05 | 2005-06-29 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
GT200200183A (es) | 2001-09-28 | 2003-05-23 | Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol | |
WO2003037336A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
PL372962A1 (en) | 2002-04-08 | 2005-08-08 | Glaxo Group Limited | (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives |
HUE039881T2 (hu) | 2002-05-09 | 2019-02-28 | Brigham & Womens Hospital Inc | 1L1RL-1, mint egy kardiovaszkuláris betegség-marker |
GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
EP1663184A2 (en) | 2003-08-29 | 2006-06-07 | The Brigham And Women's Hospital, Inc. | Hydantoin derivatives as inhibitors of cellular necrosis |
WO2005044227A1 (en) * | 2003-11-05 | 2005-05-19 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical compositions |
US20050100594A1 (en) * | 2003-11-12 | 2005-05-12 | Nilendu Sen | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor |
EP1697746B1 (en) | 2003-12-05 | 2012-02-22 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
PL1767529T3 (pl) | 2004-06-09 | 2009-10-30 | Sumitomo Chemical Co | Pirydazynowy związek oraz jego zastosowanie |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
CA2624601C (en) | 2004-10-06 | 2018-07-03 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
WO2007016677A2 (en) | 2005-08-02 | 2007-02-08 | Nitromed, Inc. | Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
PT3279663T (pt) | 2006-03-15 | 2021-09-24 | Brigham & Womens Hospital Inc | Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias |
CA2647859C (en) | 2006-03-29 | 2016-01-05 | Nitromed, Inc. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
US20080057590A1 (en) | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
AU2008242764B2 (en) | 2007-04-18 | 2013-10-24 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
GB2462022B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
CN102548969A (zh) | 2009-08-07 | 2012-07-04 | 杜邦公司 | 杀真菌的二苯基取代哒嗪 |
SG182821A1 (en) | 2010-02-01 | 2012-08-30 | Hospital For Sick Children | Remote ischemic conditioning for treatment and prevention of restenosis |
SG10201502031XA (en) | 2010-03-31 | 2015-05-28 | Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
US9265772B2 (en) | 2012-05-11 | 2016-02-23 | Reset Therapeutics, Inc. | Carbazole-containing sulfonamides as cryptochrome modulators |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
BR112015024291A2 (pt) * | 2013-03-26 | 2017-07-18 | Sumitomo Chemical Co | método de produção de composto de piridazinona |
TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
EP3292213A1 (en) | 2015-05-04 | 2018-03-14 | Academisch Medisch Centrum | Biomarkers for the detection of aspirin insensitivity |
CN110872263B (zh) * | 2018-09-03 | 2021-09-28 | 郑州大学 | 一种化合物以及制备方法和应用 |
US20220047518A1 (en) | 2018-09-19 | 2022-02-17 | Moderna TX, Inc. | Peg lipids and uses thereof |
CA3113353A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
CN111303087B (zh) * | 2020-04-07 | 2021-08-10 | 自然资源部第三海洋研究所 | 呋喃酮类化合物及其制备方法与应用 |
CA3209491A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4891058A (pt) * | 1972-03-10 | 1973-11-27 | ||
JPS4891061A (pt) * | 1972-03-10 | 1973-11-27 | ||
JPS50121261A (pt) * | 1974-03-12 | 1975-09-23 | ||
US4302461A (en) * | 1979-08-09 | 1981-11-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory 5-substituted-2,3-diarylthiophenes |
US4427693A (en) * | 1981-08-05 | 1984-01-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines |
US5207817A (en) * | 1989-09-23 | 1993-05-04 | Bayer Aktiengesellschaft | Herbicidal 5H-furan-2-one derivatives |
EP0759432A1 (en) * | 1993-01-15 | 1997-02-26 | G.D. Searle & Co. | Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
SK20396A3 (en) * | 1993-08-19 | 1997-03-05 | Warner Lambert Co | Substituted 2(5h)furanone, 2(5h)thiophenone or 2(5h)pyrrolone derivatives and pharmaceutical compositions on their base |
US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
-
1995
- 1995-05-18 US US08/443,620 patent/US5691374A/en not_active Expired - Fee Related
-
1996
- 1996-05-15 AU AU56424/96A patent/AU707773B2/en not_active Ceased
- 1996-05-15 DK DK96913412T patent/DK0828724T3/da active
- 1996-05-15 DE DE69617676T patent/DE69617676T2/de not_active Expired - Fee Related
- 1996-05-15 CA CA002219129A patent/CA2219129A1/en not_active Abandoned
- 1996-05-15 AT AT96913412T patent/ATE210124T1/de not_active IP Right Cessation
- 1996-05-15 EP EP96913412A patent/EP0828724B1/en not_active Expired - Lifetime
- 1996-05-15 JP JP8534418A patent/JPH11505534A/ja active Pending
- 1996-05-15 WO PCT/CA1996/000306 patent/WO1996036623A1/en active IP Right Grant
- 1996-05-15 ES ES96913412T patent/ES2168471T3/es not_active Expired - Lifetime
- 1996-05-15 PT PT96913412T patent/PT828724E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996036623A1 (en) | 1996-11-21 |
US5691374A (en) | 1997-11-25 |
JPH11505534A (ja) | 1999-05-21 |
ES2168471T3 (es) | 2002-06-16 |
EP0828724A1 (en) | 1998-03-18 |
EP0828724B1 (en) | 2001-12-05 |
DK0828724T3 (da) | 2002-03-04 |
AU5642496A (en) | 1996-11-29 |
CA2219129A1 (en) | 1996-11-21 |
DE69617676T2 (de) | 2002-07-18 |
ATE210124T1 (de) | 2001-12-15 |
DE69617676D1 (de) | 2002-01-17 |
AU707773B2 (en) | 1999-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT828724E (pt) | Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2 | |
ATE189218T1 (de) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
DE69529690D1 (de) | Diaryl-2(5h)-fuaranone als cox-2-inhibitoren | |
DE69616749D1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
YU59198A (sh) | Supstituisani piridini kao selektivni inhibitori ciklooksigenaze-2 | |
NL300175I2 (nl) | Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2. | |
CA2219115A1 (en) | N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs | |
DE69825603D1 (de) | 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2 | |
ES2171723T3 (es) | 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2. | |
DE69825154D1 (de) | Pyridazinone als inhibitoren von cyclooxygenase-2 | |
CA2211320A1 (en) | 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2 | |
PL328225A1 (en) | Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors | |
DE69829861D1 (de) | 2-aminopyridine als inhibitoren von cyclooxygenase-2 | |
CA2252401A1 (en) | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors | |
CA2180624A1 (en) | Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents |